3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Ipilimumab
98
pembrolizumab
84
Nivolumab
82
aldesleukin
51
Cyclophosphamide
49
Interleukin-2
38
fludarabine phosphate
31
Vemurafenib
31
Dacarbazine
31
dabrafenib
29
trametinib
28
Temozolomide
26
fludarabine
25
CTLA-4 Antigen
18
Bevacizumab
18
Radiosurgery
15
Paclitaxel
15
Carboplatin
14
encorafenib
13
binimetinib
13
Introns
13
talimogene laherparepvec
12
Radiotherapy
12
Interferon alpha-2
12
spartalizumab
11
cobimetinib
10
atezolizumab
10
sargramostim
9
peginterferon alfa-2b
9
montanide ISA 51
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Melanoma
×
pertuzumab
×
Clear all
No trials found.